Advertisement

Topics

Bristol-Myers Squibb Company Profile

05:01 EDT 20th September 2017 | BioPortfolio

At Bristol-Myers Squibb,our mission is to extend and enhance human life by providing the highest-quality pharmaceuticals and health care products.

Location

345 Park Avenue
New York
10154-0037
United States of America

Contact

Phone: 212-546-4000
Email: corporate.communications@bms.com


News Articles [812 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb and QIAGEN collaborate

Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  predictive or prognos...

Bristol-Myers To Sell Manufacturing Facility In Swords, Ireland

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and SK Biotek Co. Ltd. announced a purchase agreement to sell Bristol-Myers Squibb's small molecule active pharmaceutical ingredient ma...

Research Analysts' Weekly Ratings Changes for Bristol-Myers Squibb

A number of firms have modified their ratings and price targets on shares of Bristol-Myers Squibb recently: 7/27/2017 - Bristol-Myers Squibb was given a new $60.00 price target on by analysts at Piper...

Bristol-Myers Squibb To Acquire IFM Therapeutics

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and IFM Therapeutics announced the companies have signed an agreement under which Bristol-Myers Squibb will acquire all of the outstand...

Bristol-Myers Squibb to Take Part in UBS Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York. Murdo Gordon, executive vice president...

Bristol-Myers Squibb Completes Acquisition of IFM Therapeutics

NewsBristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics. The transaction includes full rights to IFM’s preclinical STING and NLRP3 agonist programs focused on enhanci...

Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Seattle Genetics, Inc. (SGEN) announced a collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunothera...

Bristol-Myers Squibb to Acquire IFM Therapeutics, Strengthening its Oncology Pipeline Focus on Innate Immunity

NEW YORK & BOSTON–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which B...

PubMed Articles [99 Associated PubMed Articles listed on BioPortfolio]

A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials.

A systematic review of the Bristol-Myers Squibb normal healthy volunteers (NHVs) database identified phase 1 trials that included NHVs administered placebo with the aim of characterizing normal inter-...

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.

On December 22, 2014, the U. S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (OPDIVO®, Bristol-Myers Squibb) for the treatment of patients with unresectable or metasta...

In Reply to Myers et al.

Randomized controlled trial: Standard versus supplemental bowel preparation in patients with Bristol stool form 1 and 2.

Bristol stool form 1 and 2 is an important predictor of inadequate bowel preparation.

Prediction of Delayed Colonic Transit Using Bristol Stool Form and Stool Frequency in Eastern Constipated Patients: A Difference From the West.

The correlation between the Bristol stool form scale (BSFS) and colonic transit time (CTT) has been reported in Western populations. Our study aims to study the relationship between BSFS, stool freque...

Clinical Trials [69 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Companies [116 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Exelixis, Inc. and Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases....

More Information about "Bristol-Myers Squibb" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb news stories on BioPortfolio along with dozens of Bristol-Myers Squibb Clinical Trials and PubMed Articles about Bristol-Myers Squibb for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb Companies in our database. You can also find out about relevant Bristol-Myers Squibb Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record